method
random
doubleblind
placebocontrol
trial
adult
age
year
influenzalik
ill
posit
influenza
rapid
antigen
test
treatment
g
paracetamol
four
time
day
match
placebo
day
pernas
swab
taken
influenza
quantit
rtpcr
baselin
day
temperatur
symptom
score
record
day
time
resolut
respect
primari
outcom
variabl
area
curv
auc
quantit
pcr
viral
load
baselin
day
result
total
particip
random
one
lost
follow
one
withdrew
daysther
particip
influenza
pcrposit
placebo
paracetamol
group
respect
mean
sd
auc
pcr
viral
load
placebo
paracetamol
differ
ci
p
particip
differ
symptom
score
temperatur
time
resolut
ill
health
statu
interact
random
treatment
whether
influenza
detect
pcr
conclus
regular
paracetamol
effect
viral
shed
temperatur
clinic
symptom
patient
pcrconfirm
influenza
remain
insuffici
evid
base
paracetamol
use
influenza
infect
clinic
trial
registr
australian
new
zealand
clinic
trial
registri
despit
recommend
administ
paracetamol
symptom
relief
influenza
influenzalikeil
studi
found
regular
administr
paracetamol
effect
viral
clinic
outcom
set
bsbsbanner
editor
choic
season
pandem
influenza
infect
import
public
health
issu
effect
strategi
reduc
morbid
mortal
associ
influenza
global
health
prioriti
intern
guidelin
recommend
fever
treatment
antipyret
influenza
infect
qualif
may
help
unlik
caus
harm
howev
fever
benefici
adapt
physiolog
respons
infect
may
confer
surviv
benefit
fact
treat
fever
antipyret
could
harm
anim
treatment
antipyret
drug
increas
mortal
viral
bacteri
parasit
infect
metaanalysi
effect
antipyret
drug
therapi
anim
model
influenza
infect
found
increas
risk
mortal
odd
ratio
ci
human
paracetamol
prolong
infect
varicella
zoster
malaria
rhinoviru
impair
immun
respons
previou
random
doubleblind
placebocontrol
trial
effect
antipyret
therapi
human
influenza
infect
number
potenti
mechan
treatment
antipyret
paracetamol
may
influenc
outcom
influenza
infect
temperatur
within
human
febril
rang
enhanc
activ
cytotox
lymphocyt
cytokin
interferon
ifn
paracetamol
inhibit
polymorphonuclear
leucocyt
function
vitro
effect
augment
human
febril
temperatur
prophylact
paracetamol
time
vaccin
impair
humor
immun
respons
opsonophagocyt
activ
infant
appar
independ
effect
fever
humantrop
influenza
virus
replic
upper
respiratori
tract
natur
occur
influenza
strain
infect
human
temperatur
sensit
inhibit
replic
temperatur
within
physiolog
febril
rang
degre
temperatur
sensit
one
characterist
determin
virul
trial
investig
effect
paracetamol
viral
shed
clinic
symptom
adult
communityacquir
influenza
infect
hypothes
regular
administr
paracetamol
confirm
influenza
infect
associ
prolong
viral
shed
wors
symptom
prolong
ill
durat
conduct
random
doubleblind
placebocontrol
parallelgroup
trial
clinic
trial
unit
ctu
wellington
region
hospit
wellington
new
zealand
juli
septemb
span
two
southern
hemispher
winter
influenza
season
particip
refer
doctor
wellington
region
present
directli
studi
site
follow
public
advertis
telephon
screen
trial
prospect
regist
australian
new
zealand
clinic
trial
registri
number
url
http
wwwanzctrorgautrialregistr
trialreviewaspx
studi
receiv
nz
health
disabl
ethic
committe
approv
detail
methodolog
avail
supplementari
appendix
elig
particip
age
year
symptom
influenzalik
ill
histori
fever
document
temperatur
least
one
cough
sore
throat
rhinorrhoea
headach
myalgia
fatigu
malais
less
h
obtain
written
inform
consent
rapid
immunoassay
test
influenza
andor
b
xpect
flu
b
remel
lenexa
ks
usa
use
screen
particip
test
posit
elig
recruit
key
exclus
criteria
includ
need
hospit
admiss
regular
use
paracetamol
nonsteroid
antiinflammatori
drug
nsaid
exclud
low
dose
aspirin
particip
simplerandom
receiv
two
paracetamol
tablet
placebo
tablet
four
time
daili
day
sigma
pharmaceut
ltd
rowvil
vic
australia
doubleblind
maintain
use
ident
paracetamol
placebo
tablet
addit
studi
medic
particip
receiv
cours
oral
oseltamivir
mg
one
tablet
twice
daili
food
day
low
dose
oral
codein
avail
requir
pain
particip
admit
ctu
h
receiv
directli
observ
random
treatment
underw
standard
clinic
assess
baselin
data
collect
follow
random
follow
studi
assess
perform
pernas
flock
swab
copan
diagnost
murietta
ca
usa
collect
univers
transport
medium
roch
diagnost
basel
switzerland
taken
influenza
quantit
viral
load
revers
transcriptasepolymeras
chain
reaction
rtpcr
analysi
baselin
first
medic
dose
h
day
h
day
h
day
baselin
sampl
test
presenc
human
ribonucl
acid
rna
ensur
sampl
obtain
human
tissu
posit
instanc
multiplex
polymeras
chain
reaction
pcr
fasttrack
diagnost
junglinst
luxemburg
also
perform
baselin
sampl
respiratori
virus
addit
pernas
swab
taken
viral
cultur
baselin
day
day
blood
sampl
taken
analysi
serum
cytokin
tumour
necrosi
factor
interleukin
il
baselin
day
day
detail
virolog
methodolog
cytokin
analysi
provid
supplementari
appendix
symptom
score
record
daili
baselin
day
total
daili
symptom
score
defin
resolut
ill
particip
rate
health
visual
analogu
scale
va
worst
possibl
health
health
normal
baselin
day
day
temperatur
record
use
infrar
tympan
thermomet
liberti
health
product
melbourn
vic
australia
everi
h
durat
ctu
admiss
discharg
ctu
particip
use
thermomet
continu
record
temperatur
studi
diari
four
time
daili
final
read
record
day
schedul
ctu
appoint
advers
event
record
staff
ctu
admiss
medic
review
day
document
patient
diari
day
adher
random
treatment
day
calcul
tablet
count
return
medic
bottl
primari
outcom
variabl
area
curv
auc
quantit
pcr
influenza
viral
load
baselin
day
particip
pcr
influenzaposit
adjust
baselin
temperatur
paracetamol
use
h
prior
random
chosen
primari
outcom
variabl
may
predictor
sever
influenza
infect
predictor
risk
hospit
admiss
secondari
viral
outcom
variabl
also
applic
particip
pcr
influenzaposit
proport
decreas
viral
load
day
proport
undetect
viral
load
rtpcr
day
viral
cultur
day
secondari
clinic
outcom
applic
particip
regardless
influenza
statu
temperatur
profil
daili
maximum
daili
mean
auc
temperatur
first
h
time
resolut
ill
total
daili
symptom
score
auc
health
statu
va
day
past
research
report
standard
deviat
sd
auc
quantit
pcr
influenza
viral
load
day
unit
use
mean
sd
analysi
random
control
trial
antivir
therapi
influenza
report
differ
placebo
therapi
unit
anticip
effect
paracetamol
may
half
differ
found
antivir
therapi
total
sampl
size
two
treatment
arm
power
detect
differ
type
error
rate
statist
analysi
intentiontotreat
without
interim
analysi
primari
outcom
variabl
analyz
student
ttest
adjust
analysi
carri
analysi
covari
categor
variabl
analyz
calcul
rel
risk
risk
differ
togeth
appropri
ci
analysi
temperatur
symptom
score
auc
va
analysi
varianc
random
group
pcr
influenza
statu
interact
two
predictor
variabl
individu
temperatur
profil
plot
togeth
local
weight
scatter
plot
smoother
cox
proport
hazard
surviv
analysi
use
compar
time
symptom
resolut
sa
version
sa
institut
inc
cari
nc
usa
use
total
particip
posit
influenza
rapid
antigen
test
random
placebo
paracetamol
none
lost
follow
one
particip
withdrew
day
due
seriou
advers
event
acut
kidney
injuri
demograph
clinic
characterist
particip
shown
tabl
major
taken
antipyret
h
prior
random
median
dose
gday
paracetamol
mgday
nsaid
particip
respect
patient
refer
gener
practition
follow
attend
influenzalik
ill
particip
pcr
influenzaposit
n
n
type
n
b
n
placebo
group
paracetamol
group
fig
particip
noninfluenza
respiratori
viru
identifi
pcr
particip
viru
identifi
pcr
differ
random
group
placebo
minu
paracetamol
primari
outcom
measur
auc
quantit
influenza
pcr
viral
load
baselin
day
ci
p
tabl
estim
differ
adjust
paracetamol
use
past
h
temperatur
baselin
ci
p
tabl
show
viral
load
comparison
individu
time
point
differ
secondari
viral
outcom
variabl
tabl
cytokin
measur
supplementari
tabl
particip
influenzalik
ill
n
differ
paracetamol
placebo
group
maximum
daili
temperatur
tabl
supplementari
fig
mean
daili
temperatur
supplementari
tabl
auc
temperatur
first
h
supplementari
tabl
differ
total
daili
symptom
score
two
group
day
auc
health
statu
va
day
tabl
hazard
ratio
time
resolut
ill
placebo
versu
paracetamol
group
ci
p
fig
interact
random
treatment
whether
influenza
detect
pcr
maximum
daili
temperatur
total
daili
symptom
score
time
resolut
ill
va
tabl
maximum
daili
temperatur
day
higher
pcr
influenzaposit
versu
neg
particip
versu
mean
differ
ci
p
signific
differ
pcr
influenzaposit
versu
neg
particip
maximum
daili
temperatur
day
symptom
score
time
resolut
ill
va
pcr
influenzaposit
particip
mean
sd
maximum
daili
temperatur
day
respect
supplementari
tabl
one
particip
placebo
group
suffer
seriou
advers
event
withdrew
studi
day
one
subject
placebo
group
suffer
exacerb
asthma
requir
oral
prednison
four
particip
receiv
oral
antibiot
three
placebo
group
sinus
n
asthma
n
one
paracetamol
group
tonsil
oseltamivir
discontinu
particip
due
intoler
placebo
group
paracetamol
group
median
interquartil
rang
codein
use
first
h
mg
placebo
paracetamol
group
directli
observ
adher
investig
medicin
initi
inpati
stay
two
particip
placebo
group
four
particip
paracetamol
group
fail
return
bottl
day
adher
day
placebo
group
paracetamol
group
knowledg
first
random
doubleblind
placebocontrol
trial
effect
paracetamol
patient
confirm
influenza
infect
regular
daili
administr
maximum
recommend
dose
paracetamol
day
effect
viral
shed
temperatur
clinic
symptom
particip
pcrproven
influenza
infect
difficult
infer
benefit
harm
given
lack
effect
regular
paracetamol
administ
earli
cours
influenzalik
ill
trial
thu
recommend
practic
commun
made
base
find
number
methodolog
issu
consid
interpret
find
particip
random
within
h
symptom
onset
ensur
treatment
initi
earli
cours
ill
small
amount
paracetamol
nsaid
use
particip
random
unlik
clinic
signific
effect
natur
cours
ill
addit
variabl
time
symptom
onset
studi
entri
howev
like
mirror
happen
patient
seek
medic
advic
flulik
symptom
despit
predetermin
random
schedul
data
collect
one
particip
six
particip
influenza
aposit
two
particip
influenza
bposit
respiratori
virus
identifi
rhinoviru
n
coronaviru
n
parainfluenza
n
respiratori
syncyti
viru
n
rhinoviru
coronaviru
n
particip
noninfluenza
respiratori
viru
identifi
pcr
rhinoviru
n
coronaviru
n
parainfluenza
n
respiratori
syncyti
viru
n
enteroviru
n
rhinoviru
parainfluenza
n
particip
viru
identifi
pcr
nsaid
nonsteroid
antiinflammatori
drug
pcr
polymeras
chain
reaction
sd
standard
deviat
larger
number
particip
placebo
group
chronic
respiratori
condit
andor
season
influenza
vaccin
compar
control
group
unclear
extent
characterist
may
influenc
particip
symptom
score
particip
admit
ctu
first
h
trial
period
consequ
period
full
complianc
studi
drug
temperatur
record
complet
accur
adher
medic
discharg
approxim
group
particip
administ
cours
oseltamivir
accord
intern
recommend
manag
influenza
infect
time
protocol
develop
although
may
reduc
ill
sever
viral
load
effect
oseltamivir
would
across
paracetamol
placebo
group
howev
possibl
use
may
reduc
abil
detect
signific
differ
random
treatment
primari
outcom
patient
recruit
follow
attend
tabl
maximum
daili
temperatur
total
daili
symptom
score
auc
health
statu
va
accord
random
treatment
random
particip
interact
influenza
pcr
statu
random
treatment
primari
healthcar
clinic
influenzalik
ill
find
generaliz
manag
otherwis
healthi
adult
influenzalik
ill
proven
influenza
infect
commun
number
altern
explan
find
differ
random
group
apart
fact
paracetamol
affect
influenza
outcom
studi
recruit
pcrconfirm
case
despit
screen
rapid
antigen
test
kit
report
diagnost
specif
influenza
b
baselin
pernas
sampl
contain
human
rna
indic
lower
expect
result
unlik
due
poor
sampl
techniqu
possibl
specif
rapid
antigen
test
reduc
studi
due
cross
reactiv
respiratori
virus
lower
anticip
number
pcrposit
influenza
case
might
expect
reduc
statist
power
detect
differ
sd
primari
outcom
variabl
substanti
less
anticip
past
research
ci
differ
exclud
differ
expect
detect
half
magnitud
seen
antivir
treatment
influenza
may
smaller
differ
primari
outcom
variabl
still
clinic
relev
term
clinic
outcom
variabl
paracetamol
signific
antipyret
effect
whether
measur
daili
maximum
daili
mean
auc
temperatur
h
may
due
part
modest
febril
respons
particip
mean
maximum
temperatur
day
influenza
pcrposit
group
fall
day
due
lack
antipyret
efficaci
sampl
unabl
test
hypothesi
suppress
fever
paracetamol
influenza
infect
may
harm
find
rais
question
antipyret
efficaci
paracetamol
influenza
respiratori
infect
previou
studi
paracetamol
proven
influenza
infect
adult
children
found
two
studi
paracetamol
adult
upper
respiratori
tract
infect
one
studi
report
nonsignific
reduct
temperatur
regular
paracetamol
compar
placebo
presum
nonbacteri
upper
respiratori
tract
infect
studi
compar
singl
dose
paracetamol
placebo
acut
febril
adult
upper
respiratori
tract
symptom
report
signific
reduct
temperatur
summari
studi
found
regular
administr
paracetamol
effect
viral
shed
temperatur
symptom
ill
durat
patient
pcrconfirm
influenza
infect
influenzalik
ill
also
treat
oseltamivir
prioriti
undertak
studi
ascertain
riskbenefit
profil
routin
use
paracetamol
alon
treatment
presum
pcrconfirm
influenza
infect
otherwis
healthi
adult
commun
mean
sd
temperatur
degre
celsiu
studi
particip
day
placebo
paracetamol
area
curv
degre
celsiu
studi
particip
initi
period
enrol
studi
placebo
paracetamol
maximum
daili
temperatur
subgroup
defin
influenza
pcr
statu
random
treatment
rel
risk
confid
interv
differ
proport
detect
placebo
paracetamol
group
differ
logarithm
cytokin
expon
logarithm
interpret
ratio
mean
valu
